UTILIDAD CLINICA DEL NT-ProBNP EN PACIENTES CON INSUFICIENCIA RENAL CRÓNICA AVANZADA Y EN HEMODIÁLIS
Clinical use of NT-PRO-BNP in end stage renal failure patients
M. Heras, M.J. Fernandez Reyes, P. Guevara, R. Sanchez, M. Gonzalez, S. Velasco, M.C. Garcia Arevalo, F. Alvarez-Ude
Leído
32272
Vecesse ha leído el artículo
7582
Total PDF
24690
Total HTML
Información del artículo
ISSN: 02116995Idioma original: Español
Datos actualizados diariamente
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 6 | 170 | 78 | 248 |
| 2025 5 | 272 | 83 | 355 |
| 2025 4 | 271 | 85 | 356 |
| 2025 3 | 286 | 136 | 422 |
| 2025 2 | 283 | 100 | 383 |
| 2025 1 | 335 | 120 | 455 |
| 2024 12 | 246 | 98 | 344 |
| 2024 11 | 272 | 115 | 387 |
| 2024 10 | 311 | 166 | 477 |
| 2024 9 | 321 | 112 | 433 |
| 2024 8 | 281 | 134 | 415 |
| 2024 7 | 290 | 93 | 383 |
| 2024 6 | 297 | 94 | 391 |
| 2024 5 | 299 | 81 | 380 |
| 2024 4 | 297 | 137 | 434 |
| 2024 3 | 248 | 97 | 345 |
| 2024 2 | 239 | 78 | 317 |
| 2024 1 | 281 | 82 | 363 |
| 2023 12 | 248 | 67 | 315 |
| 2023 11 | 332 | 100 | 432 |
| 2023 10 | 300 | 95 | 395 |
| 2023 9 | 259 | 85 | 344 |
| 2023 8 | 262 | 83 | 345 |
| 2023 7 | 257 | 122 | 379 |
| 2023 6 | 288 | 113 | 401 |
| 2023 5 | 238 | 110 | 348 |
| 2023 4 | 226 | 106 | 332 |
| 2023 3 | 257 | 67 | 324 |
| 2023 2 | 227 | 59 | 286 |
| 2022 1 | 209 | 67 | 276 |
| 2022 12 | 169 | 63 | 232 |
| 2022 11 | 243 | 80 | 323 |
| 2022 10 | 245 | 85 | 330 |
| 2022 9 | 200 | 68 | 268 |
| 2022 8 | 170 | 79 | 249 |
| 2022 7 | 187 | 84 | 271 |
| 2022 6 | 192 | 70 | 262 |
| 2022 5 | 202 | 96 | 298 |
| 2022 4 | 197 | 89 | 286 |
| 2022 3 | 183 | 93 | 276 |
| 2022 2 | 187 | 84 | 271 |
| 2021 1 | 234 | 77 | 311 |
| 2021 12 | 164 | 100 | 264 |
| 2021 11 | 145 | 81 | 226 |
| 2021 10 | 170 | 90 | 260 |
| 2021 9 | 217 | 57 | 274 |
| 2021 8 | 125 | 57 | 182 |
| 2021 7 | 185 | 43 | 228 |
| 2021 6 | 203 | 57 | 260 |
| 2021 5 | 230 | 83 | 313 |
| 2021 4 | 406 | 116 | 522 |
| 2021 3 | 345 | 56 | 401 |
| 2021 2 | 317 | 61 | 378 |
| 2020 1 | 245 | 38 | 283 |
| 2020 12 | 249 | 50 | 299 |
| 2020 11 | 268 | 62 | 330 |
| 2020 10 | 204 | 32 | 236 |
| 2020 9 | 220 | 14 | 234 |
| 2020 8 | 178 | 32 | 210 |
| 2020 7 | 198 | 35 | 233 |
| 2020 6 | 244 | 46 | 290 |
| 2020 5 | 188 | 37 | 225 |
| 2020 4 | 169 | 33 | 202 |
| 2020 3 | 340 | 23 | 363 |
| 2020 2 | 236 | 36 | 272 |
| 2020 1 | 271 | 36 | 307 |
| 2019 12 | 220 | 35 | 255 |
| 2019 11 | 229 | 32 | 261 |
| 2019 10 | 297 | 698 | 995 |
| 2019 9 | 292 | 34 | 326 |
| 2019 8 | 288 | 25 | 313 |
| 2019 7 | 329 | 46 | 375 |
| 2019 6 | 290 | 31 | 321 |
| 2019 5 | 250 | 33 | 283 |
| 2019 4 | 281 | 55 | 336 |
| 2019 3 | 197 | 30 | 227 |
| 2019 2 | 150 | 34 | 184 |
| 2019 1 | 125 | 24 | 149 |
| 2018 12 | 132 | 49 | 181 |
| 2018 11 | 165 | 55 | 220 |
| 2018 10 | 143 | 52 | 195 |
| 2018 9 | 182 | 58 | 240 |
| 2018 8 | 186 | 52 | 238 |
| 2018 7 | 124 | 25 | 149 |
| 2018 6 | 149 | 35 | 184 |
| 2018 5 | 151 | 20 | 171 |
| 2018 4 | 129 | 25 | 154 |
| 2018 3 | 110 | 24 | 134 |
| 2018 2 | 104 | 19 | 123 |
| 2018 1 | 114 | 17 | 131 |
| 2017 12 | 114 | 41 | 155 |
| 2017 11 | 103 | 27 | 130 |
| 2017 10 | 110 | 19 | 129 |
| 2017 9 | 79 | 35 | 114 |
| 2017 8 | 93 | 28 | 121 |
| 2017 7 | 78 | 15 | 93 |
| 2017 6 | 92 | 46 | 138 |
| 2017 5 | 82 | 25 | 107 |
| 2017 4 | 65 | 34 | 99 |
| 2017 3 | 44 | 66 | 110 |
| 2017 2 | 39 | 54 | 93 |
| 2016 1 | 47 | 87 | 134 |
| 2016 12 | 60 | 51 | 111 |
| 2016 11 | 94 | 90 | 184 |
| 2016 10 | 118 | 81 | 199 |
| 2016 9 | 175 | 41 | 216 |
| 2016 8 | 287 | 56 | 343 |
| 2016 7 | 303 | 72 | 375 |
| 2016 6 | 212 | 0 | 212 |
| 2016 5 | 247 | 0 | 247 |
| 2016 4 | 183 | 0 | 183 |
| 2016 3 | 118 | 0 | 118 |
| 2016 2 | 160 | 0 | 160 |
| 2015 1 | 153 | 0 | 153 |
| 2015 12 | 150 | 0 | 150 |
| 2015 11 | 110 | 0 | 110 |
| 2015 10 | 116 | 0 | 116 |
| 2015 9 | 112 | 0 | 112 |
| 2015 8 | 127 | 0 | 127 |
| 2015 7 | 166 | 0 | 166 |
| 2015 6 | 73 | 0 | 73 |
| 2015 5 | 101 | 0 | 101 |
| 2015 4 | 10 | 0 | 10 |
| 2015 3 | 1 | 0 | 1 |
| 2015 2 | 3 | 0 | 3 |
Mostrar todo
